Completed PHASE3 INTERVENTIONAL 2-arm NCT00684632

A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients

Sponsor: Kyowa Kirin Co., Ltd.

Interventions KW-2246 (fentanyl citrate) Placebo

Updated 9 times since 2017 Last updated: Aug 27, 2020 Started: Mar 31, 2008 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00684632, this PHASE3 trial focuses on Pain, Cancer and remains completed. Sponsored by Kyowa Kirin Co., Ltd., it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Aug 2019 — Sep 2020 [monthly]

Completed PHASE3
Jun 2018 — Aug 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyowa Kirin Co., Ltd.

Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Azumino, Japan , Bunkyo-ku, Japan , Ibaraki, Japan , Izumisano, Japan , Kanazawa, Japan , Kasama, Japan , Katori-shi, Japan , Kitakyushu, Japan , Kumamoto, Japan , Kōriyama, Japan and 10 more locations